A phase I/II, open-label, nonrandomized, dose-finding safety, tolerance, pharmacokinetic, and efficacy study of orally administered S-1 in combination with cisplatin in patients with advanced gastric cancer
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 11 Aug 2009 Actual end date (1 May 2006) added as reported by ClinicalTrials.gov
- 11 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 11 Aug 2005 New trial record.